Objective: To evaluate the role of a panel fluorescence in situ hybridization (Panel-FISH) for the detection of common cytogenetic abnormalities in patients with chronic lymphoblastic leukemia (CLL), multiplemyeloma (MM) and myelodysplastic syndrome (MDS).
Methods: Three panels of probes were used to perform FISH assays in 46 patients with CLL, 53 with MM and 93 with MDS. Their results were compared with that obtain by conventional cytogenetic examination.
Results: The panel FISH detection in CLL and MM groups showed significantly higher sensitivity in revealing chromosomal abnormalities than that in conventional cytogenetics (73.8% vs 9.5%, 70.8% vs 22.9%, respectively). There were significant differences between these 2 technologies(P<0.001, P<0.001, respectively). However, there was no difference between Panel-FISH and conventional cytogenetics in MDS group (30.4 vs 27.2%, P=0.625).
Conclusion: Panel-FISH can increase the detection rate in CLL and MM patients while it did not in MDS patients. However, it can increase the detection rate of aberration clones in MDS cases with normal karyotypes or without enough karyotypes to be analysis.